High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis.
- Published in:
- OncoTargets & Therapy, 2017, v. 10, p. 5907, doi. 10.2147/OTT.S148250
- By:
- Publication type:
- Article
Works matching AU Geqi Cha
Results: 2
1
2
Therapeutic efficacy of TMTP1-modified EVs in overcoming bone metastasis and immune resistance in PIK3CA mutant NSCLC.
- Published in:
- Cell Death & Disease, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41419-025-07685-y
- By:
- Publication type:
- Article